Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $3
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $4 to $3.